Patents by Inventor Laszlo R. Treiber

Laszlo R. Treiber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5359096
    Abstract: New cholesterol lowering compounds are formed from the photochemical treatment of the zaragozic acids.
    Type: Grant
    Filed: November 20, 1992
    Date of Patent: October 25, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Byron H. Arison, Shieh-Shung T. Chen, George A. Doss, Leeyuan Huang, John G. MacConnell
  • Patent number: 5322855
    Abstract: Zaragozic acids isolated from a culture of MF5465 have been subjected to photoreaction, then derivatized at the 4-keto position. The resulting derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.
    Type: Grant
    Filed: November 24, 1992
    Date of Patent: June 21, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Doss, George A., Byron H. Arison
  • Patent number: 5264593
    Abstract: This invention relates to compounds of structural formula ##STR1## which are inhibitors of squalene synthase and useful as cholesterol lowering agents.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: November 23, 1993
    Assignee: Merck & Co., Inc.
    Inventor: Laszlo R. Treiber
  • Patent number: 5225403
    Abstract: Described is a process for producing a new FK-506 antagonist agent, a C-21 hydroxylated analog of FR-900520 under novel fermentation conditions utilizing the novel microorganism, Streptomyces hygroscopicus (Merck Culture Collection MA 6832) ATCC No. 55166. The macrolide antagonist is useful in preventing and/or counteracting accidental or inadvertent FK-506 overdosage in an FK-506 therapeutic program designed to prevent autoimmune diseases or human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: June 25, 1991
    Date of Patent: July 6, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Georgette Dezeny, Lawrence F. Colwell, Jr., Byron H. Arison, Francis Dumont
  • Patent number: 5192668
    Abstract: A dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: March 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Lawrence F. Colwell, Jr., Byron H. Arison, Georgette Dezeny, Russell B. Lingham, Wayne J. Thompson, Suresh K. Balani
  • Patent number: 5187074
    Abstract: A novel dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 20, 1992
    Date of Patent: February 16, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Russell B. Lingham, Byron H. Arison, Lawrence F. Colwell, Jr., Georgette Dezeny, Nancy E. Kohl
  • Patent number: 4916239
    Abstract: A process for the lactonization of mevinic acid HMG-CoA reductase inhibitors and analogs thereof is disclosed.
    Type: Grant
    Filed: July 19, 1988
    Date of Patent: April 10, 1990
    Assignee: Merck & Co., Inc.
    Inventor: Laszlo R. Treiber
  • Patent number: 4719229
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents are represented by the following structural formulae (I) and (II): ##STR1## are disclosed.
    Type: Grant
    Filed: May 13, 1987
    Date of Patent: January 12, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Robert A. Reamer, Laszlo R. Treiber
  • Patent number: 4399274
    Abstract: Non-ionic, lipophilic substances are isolated from aqueous or aqueous-organic solution by treatment with a macroreticular polymeric absorbent followed by elution with additional or a different organic solvent.
    Type: Grant
    Filed: July 2, 1981
    Date of Patent: August 16, 1983
    Assignee: Merck & Co., Inc.
    Inventors: Robert T. Goegelman, Laszlo R. Treiber
  • Patent number: 4198338
    Abstract: Fermentation broths or impure solutions containing thienamycin, a substance having antibiotic activity against gram-negative and gram-positive microorganisms, are purified using a sequence of ion exchange resins, starting with an anion exchange resin of the polystyrene-trimethylammonium type in the HCO.sub.3 -cycle, and ending with absorption on and elution from a polymeric cross-linked polystyrene-type resin adsorbent. Variations in the intermediate steps, e.g. different resins and eluates are possible and are illustrated within.
    Type: Grant
    Filed: March 13, 1978
    Date of Patent: April 15, 1980
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Vincent P. Gullo